TMS Co., Ltd.

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Orum, Vertex Ink Novel Protein-Deg

Biogen, Inc. underscored its commitment to Alzheimer’s disease while announcing the discontinuation of three clinical-stage development programs as new CEO Christopher Viehbacher continues to piece t

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Genentech/Pieris Pact Follows Abandoned

Biogen, Inc. ’s second quarter financial performance exceeded expectations on 22 July, but longer-term concerns continue to weigh on the company, which is betting its future on the uncertain US Food a